This study is aimed to evaluate the efficacy and safety of Fosrolapitant and Palonosetron for Antibody-drug conjugate-induced nausea and vomiting
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
124
• Experimental: Drug:Fosrolapitant and Palonosetron for injection Drug:Dexamethasone Drug: placebo • Active Comparator: Drug:HR20013 placebo Drug: fosaprepitant dimeglumine for injection Drug:Palonosetron injection Drug: Dexamethasone
Complete response rate
Time frame: Within 14 days after ADC administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.